Pro-Dex (NASDAQ:PDEX) Shares Pass Above 200-Day Moving Average of $17.72

Pro-Dex, Inc. (NASDAQ:PDEX)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.72 and traded as high as $18.15. Pro-Dex shares last traded at $18.15, with a volume of 4,020 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Pro-Dex from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th.

Pro-Dex Stock Up 1.9 %

The firm has a 50-day moving average of $17.91 and a two-hundred day moving average of $17.72. The company has a quick ratio of 2.16, a current ratio of 3.66 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $63.72 million, a PE ratio of 24.20 and a beta of 0.60.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.14 earnings per share for the quarter. The business had revenue of $12.59 million during the quarter. Pro-Dex had a return on equity of 8.97% and a net margin of 5.59%.

Institutional Investors Weigh In On Pro-Dex

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in Pro-Dex by 59.2% during the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 7,762 shares in the last quarter. LSV Asset Management lifted its position in Pro-Dex by 13.9% in the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock valued at $588,000 after acquiring an additional 4,346 shares during the last quarter. State Street Corp boosted its stake in Pro-Dex by 5.8% in the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock valued at $197,000 after acquiring an additional 650 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Pro-Dex during the second quarter worth about $168,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Pro-Dex by 345.6% during the third quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 2,084 shares in the last quarter. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.